PERTH, Australia – After signing a deal with Nantworks Inc. that expands its pipeline into oncology, Australian gene silencing company Benitec Biopharma Ltd. appears to be on the road to recovery after a few harrowing years that sent the stock into a nosedive.
PERTH, Australia – After announcing its plans for an IPO on Nasdaq, Aussie biotech Immuron Ltd. said it is ramping up its phase II program for its immunotherapy IMM-124E in non-alcoholic steatohepatitis (NASH).
PERTH, Australia – Australian regenerative medicine company Orthocell Ltd. got the validation it needed to move from being a small little-known Western Australian biotech company to move to the global stage via a research collaboration with Depuy Synthes Products for its Ortho-ATI stem cell technology for regenerating tendons and ligaments.
PERTH, Australia – Proposed recommendations to update Australia's intellectual property (IP) system would be disastrous to the biopharma industry and would put a stranglehold on innovation and investment, industry stakeholders said.
PERTH, Australia – Australian regenerative medicine company Orthocell Ltd. got the validation it needed to move from being a small little-known Western Australian biotech company to move to the global stage via a research collaboration with Depuy Synthes Products for its Ortho-ATI stem cell technology for regenerating tendons and ligaments.
PERTH, Australia – Proposed recommendations to update Australia's intellectual property (IP) system would be disastrous to the biopharma industry and would put a stranglehold on innovation and investment, industry stakeholders said.
DUBLIN – Chicago Cubs fans excepted, 2016 was a bad year for many for a whole host of reasons. The travails of the Australian cell therapy developer Mesoblast Ltd. may not have registered broadly, but the firm had a torrid year.
DUBLIN – Chicago Cubs fans excepted, 2016 has been a bad year for many for a whole host of reasons. The travails of the Australian cell therapy developer Mesoblast Ltd. may not have registered broadly, but the firm has had a torrid year.
